Does anyone know the potential addressable market for this treatment (all going well) in the APAC region excluding 'greater china'? I guess India is amongst those countries but unsure of their actual market size for cancer treatment along with the others.
There seems to be bit of comparison to early stage imu but this I believe is a marked difference in the two companies potential and may limit ivx well below imu. Thoughts?
Add to My Watchlist
What is My Watchlist?
